Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

CareMed, BioCryst Pharmaceuticals partner on rare disease drug Orladeyo national pharmacy distribution
Pharmacy partnership, rare disease, small molecule, commercialization - Read more

AstraZeneca's tozorakimab cuts exacerbations by ~30% in Ph3 chronic obstructive pulmonary disease trials
Antibody, respiratory disease, monoclonal antibody, COPD, IL-33 target - Read more

Amgen's Imdelltra (tarlatamab-dlle) meets Ph3 OS endpoint as maintenance therapy for extensive-stage small-cell lung cancer
Antibody, cancer, bispecific T-cell engager, small-cell lung cancer, DLL3 target, maintenance therapy - Read more

Beeline Medicines' (afimetoran) hits Ph2 primary endpoint in systemic lupus erythematosus, advancing to Ph3
Small molecule, autoimmune, TLR7/8 inhibitor, lupus, systemic lupus erythematosus - Read more

BioMarin submits FDA expansion filing for Voxzogo (vosoritide) in hypochondroplasia following Ph3 trial success
Protein therapy, skeletal disorder, C-type natriuretic peptide, achondroplasia, hypochondroplasia, FGFR3 - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Schrödinger launches Tectora Therapeutics with $55M Series A to develop oral immunology and inflammation medicines
Small molecule, autoimmune, strategic, major transaction - Read more

Solstice Oncology launches with $225M to advance next-generation CTLA-4 cancer immunotherapy into mid-stage trials
Immuno-oncology, antibody, CTLA-4, colorectal cancer, clinical-stage - Read more

Caspian Therapeutics launches with $50M and Eli Lilly backing to advance disease-modifying diabetes treatment
Small molecule, diabetes, strategic, major transaction - Read more

Encoded Therapeutics raises $275M Series F, advancing Dravet syndrome gene therapy and manufacturing
Neurological, gene therapy, rare disease, AAV, Dravet syndrome, manufacturing - Read more

Luma Group closes $410M inaugural life sciences venture capital fund, 15-year investment horizon
Venture capital, life sciences, ophthalmology, cellular rejuvenation, nanoparticle technology - Read more

Cloverleaf Bio raises $33M Seed funding to advance tRNA-based cancer therapeutics
RNA therapeutics, cancer, oncology, preclinical, clinical-stage - Read more

ViaNautis Bio receives undisclosed SCI Ventures investment to expand CNS portfolio into spinal cord injury
Non-viral gene delivery, CNS, nanovesicle platform, spinal cord injury, mRNA delivery - Read more

Allogenetics raises €3.8M ($4.42M) Pre-Series A, advancing ex vivo gene therapy for organ transplantation
Gene therapy, organ transplantation, ex vivo, preclinical, immunosuppression - Read more

Inno Medicine raises RMB 800M ($119.25M) Series D to advance active targeting liposome therapy clinical trials
Liposome therapy, cardiovascular, oncology, clinical-stage - Read more

Sandoz invests $2.5B to build vertically integrated biosimilar manufacturing network, targeting 100 biosimilars by 2040
Biosimilar, multi-disease, manufacturing, major transaction - Read more

Labcorp acquires MLM Medical Labs to expand global laboratory network across four continents
Laboratory services, clinical trials, strategic, major transaction - Read more

Sernova Biotherapeutics, Seraxis merge to form BetaNova Biotherapeutics, a clinical-stage Type 1 diabetes islet cell-replacement company
Cell therapy, type 1 diabetes, major transaction, financial - Read more

Gilead Sciences' Livdelzi accepted by Scottish Medicines Consortium for NHS Scotland PBC treatment
Small molecule, rare disease, autoimmune, regulatory - Read more

FDA names permanent CBER and CDER heads, signaling leadership stability amid ongoing agency restructuring
Leadership continuity, regulatory, operational, FDA stability - Read more

BrYet receives AIFA approval for cGMP manufacturing line, enabling ML-016 clinical supply to Australia
Small molecule, oncology, operational, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Evommune's EVO756 (oral MRGPRX2 antagonist) fails Ph2b trial in moderate-to-severe atopic dermatitis, ending programme
Small molecule, autoimmune, MRGPRX2 antagonist, atopic dermatitis, oral therapy - Read more

Shionogi, StemRIM's (redasemtide) Ph2b trial misses primary endpoint in acute ischaemic stroke
Protein therapy, neurological, regeneration-inducing medicine, acute ischaemic stroke, HMGB1, mesenchymal stem cells - Read more

Tyra Biosciences' (dabogratinib) Ph2 data misses expectations in FGFR3-altered non-muscle invasive bladder cancer, Ph3 planned
Small molecule, cancer, FGFR3 inhibitor, bladder cancer, non-muscle invasive bladder cancer - Read more

Merck & Co. cuts 54 more New Jersey jobs in multiyear $3B cost-saving initiative targeting 6,000 global positions
Workforce reduction, oncology, cost reduction, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here